Synonyms: Margenza® | margetuximab-cmkb | MGAH-22
margetuximab is an approved drug (FDA (2020))
Compound class:
Antibody
Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 [2]. Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a KD value is not provided. |
References |
1. Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK. (2021)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol, 17 (10): 1155-1164. [PMID:33263418] |
2. Johnson LS, Huang L, Tuaillon N, Bonvini E. (2014)
HER2/neu-specific antibodies and methods of using same. Patent number: US8802093 B2. Assignee: Macrogenics, Inc.. Priority date: 02/04/2008. Publication date: 12/08/2014. |